The Latest

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

By Martha Kempner

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base

UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants

The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.

By Simon Collins for HIV i-Base

What Is the State of the Art in HIV Treatment and Prevention?

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

By Sony Salzman

How Will Long-Acting HIV Antiretrovirals Work in the Real World?

Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.

By Terri Wilder, M.S.W.

NIH Clinical Trial to Track Outcomes of Kidney Transplantation From HIV-Positive Donors to HIV-Positive Recipients

The first large-scale clinical trial to study kidney transplantations between people with HIV has begun at clinical centers across the U.S.

By National Institues of Health

Gene Therapy in HIV Cure Research

There is a great deal of interest in exploring the potential of gene therapy to cure HIV and multiple gene therapy strategies are under investigation.

By Richard Jefferys for Positively Aware

Why Finding New HIV Targets Takes So Long: Some Basics About Basic Research

The death toll from HIV/AIDS continues to decline, but more than 36 million people are still living with HIV. A researcher explains why the work for a cure is painstaking.

By Christy Gaines for The Conversation

Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017

Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...

By David Alain Wohl, M.D.

Bictegravir vs. Dolutegravir

Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange